Insys Therapeutics (INSY) Tops Q1 EPS by 1c, Miss on Revenues
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Piper Jaffray Downgrades INSYS Therapeutics (INSY) to Neutral
May 10, 2017 4:49 AM EDTPiper Jaffray downgraded INSYS Therapeutics (NASDAQ: INSY) from Overweight to Neutral with a price target of $10.00 (from $20.00).
Analyst David Amsellem cites lacking clarity on the progress of the recent investigation regarding opiods and also cites a lack of clairty when it... More
